In summary, we revealed 2 immunologically distinct subtypes in terms of immune infiltration, PD-L1 expression, and response to immunotherapy with comparable TMB and clinical features, indicating that HR+/HER2– breast cancer possessed a highly heterogeneous immune environment. This evidence concerns the gene ERBB2 and breast cancer.